Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib in Refractory Primary Bone Tumors
NCT05395741Phase 2Completed
- Sponsor
- Institute of Mother and Child
- Start
- Apr 2022
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of regorafenib in osteosarcoma (OS), Ewing sarcoma, sponsored by Institute of Mother and Child. Started Apr 2022; status: completed.
02
Drugs
regorafenib
03
Conditions
osteosarcoma (OS)Ewing sarcoma
Beyond the preview
Go deeper on NCT05395741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05395741.